Novel MS solutions inspired by MIST
- 1 July 2010
- journal article
- review article
- Published by Future Science Ltd in Bioanalysis
- Vol. 2 (7), 1291-1313
- https://doi.org/10.4155/bio.10.83
Abstract
To improve patient safety and to help avoid costly late-stage failures, the pharmaceutical industry, along with the US FDA and International Committee on Harmonization (ICH), recommends the identification of differences in drug metabolism between animals used in nonclinical safety assessments and humans as early as possible during the drug-development process. LC–MS is the technique of choice for detection and characterization of metabolites, however, the widely different LC–MS response observed for a new chemical entity (NCE) and its structurally related metabolites limits the direct use of LC–MS responses for quantitative determination of NCEs and metabolites. While no method provides completely accurate universal response, UV, corona charged aerosol detection (CAD), radioactivity, NMR and low-flow (<20 µl/min) nanospray approaches provide opportunities to quantify metabolites in the absence of reference standards or radiolabeled material with enough precision to meet the needs of early clinical development.Keywords
This publication has 49 references indexed in Scilit:
- Quantitative determination of hippuric and benzoic acids in urine by LC–MS/MS using surrogate standardsJournal of Pharmaceutical and Biomedical Analysis, 2010
- Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicityChemico-Biological Interactions, 2010
- Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicityToxicology Letters, 2010
- Fractional mass filtering as a means to assess circulating metabolites in early human clinical studiesRapid Communications in Mass Spectrometry, 2008
- Evolving Role of Mass Spectrometry in Drug Discovery and DevelopmentPublished by Wiley ,2008
- High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolitesAnalytical and Bioanalytical Chemistry, 2008
- Key elements of bioanalytical method validation for small moleculesThe AAPS Journal, 2007
- Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolitesToxicology and Applied Pharmacology, 2006
- Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detectionJournal of Pharmaceutical and Biomedical Analysis, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004